The association between medication use and gait in adults with intellectual disabilities by Maas, S. (S.) et al.
The association between medication use and gait in adults
with intellectual disabilities
S. Maas,1 D. A. M. Festen,1 T. I. M. Hilgenkamp1,2 & A. Oppewal1
1 Intellectual Disability Medicine, Department of General Practice, Erasmus MC University Medical Center Rotterdam, Rotterdam,
The Netherlands
2 Department of Physical Therapy, University of Nevada, Las Vegas, NV, USA
Abstract
Background Adults with intellectual disabilities (ID)
often have polypharmacy and often use
antipsychotics. Both polypharmacy and antipsychotics
have a negative effect on gait in the general
population, but this has not been studied in adults
with ID. These negative effects may add to
pre-existing gait disturbances in adults with ID and
increase the risk for adverse health outcomes in this
population. Therefore, the aim of this study is to
investigate the difference in gait parameters between
adults with ID with and without polypharmacy and
between adults with ID using and not using
antipsychotics.
Method The gait parameters of 31 participants were
collected with the GAITRite walkway, a pressure
sensitive walkway measuring spatial and temporal gait
parameters, in addition to information about personal
characteristics, prescribed medication and presence
of polypharmacy.
Results After adjustment for sex and body mass
index, participants with polypharmacy had a
significantly shorter step length [polypharmacy B
(SE) ¼ 0.079 (0.034), P ¼ 0.03], shorter stride
length [polypharmacy B (SE) ¼ 0.157 (0.069),
P ¼ 0.03] and longer double support time
[polypharmacy B (SE) ¼ 0.0004 (0.0001),
P ¼ 0.047]. Participants using antipsychotics had a
significantly longer double support time
[antipsychotic use B (SE) ¼ 0.0003 (0.0002),
P ¼ 0.019].
Conclusion This study showed for the first time that
both polypharmacy and using antipsychotics are
associated with gait in adults with ID. The differences
seem to resemble a more cautious gait. Further
investigation with larger study samples, additional
medication types and dosages are needed to acquire
more insight in this important topic.
Keywords antipsychotics, gait, intellectual
disabilities, motor control, polypharmacy
Introduction
People with intellectual disabilities (ID) have a high
risk of developing physical and mental disorders and
often experience multimorbidity (Hermans and
Evenhuis 2014). As a result, people with ID often use
multiple medications, and polypharmacy (taking five
or more prescribed medications) is very common.
Recent studies have shown that polypharmacy rates in
adults with ID range between 20% and 40% (Peklar
et al. 2017; O’Dwyer et al. 2018; Schoufour
et al. 2018). These high prevalence rates are a serious
problem because polypharmacy increases the risk of
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prescription errors, drug–drug interaction and
adverse reactions, and polypharmacy has been found
to be a strong independent predictor for mortality in
adults with ID (Zaal et al. 2013; Sharifi et al. 2014;
Schoufour et al. 2018).
Among these adverse reactions are the potential
negative effects of polypharmacy on motor skills, and
in particular gait, of adults with ID. This is of
particular importance, because people with ID often
already have delayed motor development, which is
interrelated to their impaired cognitive development
(Diamond 2000). In a previous study, we found that
gait of adults with ID was rather similar to the gait
seen in older adults in the general population who
were on average 20 years older, thereby already
resembling an older gait pattern (Oppewal
et al. 2018). Adults with ID also seemed to have a
more variable and broader gait pattern (Oppewal
et al. 2018). Furthermore, certain genetic syndromes
causing ID can also result in specific gait
disturbances. For example, people with Down
syndrome (DS) often have typical physical features,
such as decreased muscle tone and a wider spacing
between the toes causing instability, which can
contribute to gait disturbances (Herman et al. 2005).
However, because people with heterogeneous or
unknown aetiology of ID present with gait
disturbances too, these disturbances cannot be solely
attributed to specific genetic syndromes (Herman
et al. 2005; Almuhtaseb et al. 2014).
Gait disturbances are increasingly being linked to
poor health outcomes in the general population, and
gait is therefore an important marker for one’s health.
Disturbances in gait are predictive for falls, future
disability, cognitive impairment, institutionalisation
and mortality (Verghese et al. 2006; Verghese
et al. 2007; Hollman et al. 2011). The potential
negative effects of polypharmacy on gait are therefore
a major concern. Several studies in the general
population have shown that polypharmacy negatively
affects gait and leads to more disability in mobility
and daily functioning (Gnjidic et al. 2012; Langeard
et al. 2016). This association seems to be independent
of the underlying diseases (Langeard et al. 2016). In
the general population, polypharmacy has been found
to be associated with slower gait velocity, higher stride
length and stride time, more variation in stride time,
longer step length, step width, and step time, and
higher double support time (Montero-Odasso
et al. 2019). However, no studies regarding this have
been done in adults with ID.
Besides polypharmacy, psychotropic medication
specifically is found to negatively influence gait and
motor skills in the general population (American
Geriatrics Society 2001; Rubino 2002; de Groot
et al. 2016), and the use of psychotropic medication is
considered a risk factor for acquiring gait disturbances
in elderly (Hartikainen et al. 2007; Bloch et al. 2011; de
Groot et al. 2016). For example, antipsychotics can
influence motor skills by causing orthostatic
hypotension and extrapyramidal side effects
(Arana 2000; Ucok and Gaebel 2008). In adults with
ID, we see a high prevalence of the use of psychotropic
medication, with studies showing that roughly 30% to
40% of adults with ID use at least one psychotropic
medication (van Schrojenstein Lantman-de Valk
et al. 1995; Matson and Mahan 2010; Boot 2017).
Especially the use of antipsychotics is highly prevalent,
both in community (17%–27%) and inpatient (35%–
56%) settings (de Kuijper et al. 2010; de Kuijper and
Hoekstra 2017; Doan et al. 2013; Robertson
et al. 2000; Sheehan et al. 2015). There are some
studies in people with ID that show that antipsychotics
negatively impact movement such as tardive
dyskinesia, akathisia and parkinsonism (Matson and
Mahan 2010). However, no studies have looked at the
effects of antipsychotics on gait in adults with ID. The
results seen in the general population cannot be
generalised to adults with ID because people with ID
may have more adverse effects of antipsychotics
(Matson and Mahan 2010; Sheehan et al. 2017). Also,
as mentioned previously, adults with ID often already
have pre-existing gait disturbances (Almuhtaseb
et al. 2014). These pre-existing gait disturbances make
it difficult to assess the additional adverse effects of
polypharmacy and antipsychotic use on the gait of
adults with ID, and this is a field that is rarely studied.
Understanding the effects of polypharmacy and the
use of antipsychotics on gait is therefore of utmost
importance in adults with ID, because any additional
negative effects on an already poor gait may
exponentially increase the risk for adverse health
outcomes, such as falls and disability in daily
functioning. Therefore, the aim of this study is to
investigate the difference in gait parameters between
adults with ID with and without polypharmacy, and
between adults with ID using and not using
antipsychotics.
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Method
Study design and participants
This cross-sectional quantitative exploratory study
was performed within the Healthy Ageing and
Intellectual Disabilities consortium, a collaboration of
the Chair of Intellectual Disability Medicine of the
Erasmus MC University Medical Center Rotterdam
and three care organisations for people with ID in the
Netherlands. Clients aged 20 years or older, with the
ability to walk without walking aids and an IQ
between 35 and 69 (classified as mild to moderate
ID), were eligible for this study. Clients with a
diagnosis of DS, Parkinson’s disease, dementia, a
history of cerebrovascular accidents, cerebral palsy or
a vision below 0.3 were excluded due to the possible
influences these conditions might have on gait.
Behavioural therapists and medical doctors working
at the participating care organisations selected
participants, living at three central locations of the
care organisations, based on these criteria. Two
hundred clients were invited to participate, resulting
in 31 participants. Because of reorganisations in the
care organisations at that time, participation rate was
lower than expected. Informed consent was obtained
from all participants and/or their legal guardians.
The Medical Ethics Review Committee from the
Erasmus MC University Medical Centre Rotterdam
approved this study (MEC-2014-201), and the study
was performed according to the guidelines of the
Declaration of Helsinki (World Medical
Association 2013).
Measurements
The data were obtained between December 2014 and
July 2015. Data were collected in a spacious room
located conveniently close to the participants.
Personal characteristics and medical information
Medical doctors and behavioural therapists from the
participating care organisations provided personal
and medical information including age, sex, level of
ID (mild ID ¼ IQ between 50 and 69 and moderate
ID ¼ IQ between 35 and 49), the use of orthopaedic
shoes, spasticity and medication use. With regard to
medication use, we collected data on polypharmacy
(using ≥5 medications, and categorised as yes/no),
the use of antipsychotics (yes/no), antidepressants
(yes/no), antiepileptics (yes/no), anxiolytics (yes/no)
and benzodiazepines (yes/no). During the data
collection, we measured height (without any shoes),
weight (light clothes and no shoes) and leg length
(from the greater trochanter to the floor, bisecting
the lateral malleolus, with the participant wearing
shoes). BMI was calculated and categorised into
normal (<25 kg/m2), overweight (25–30 kg/m2) and
obese (≥30 kg/m2) (World Health
Organisation 1995).
Gait
The GAITRite Electronic Walkway (CIR Systems,
Inc., USA; 5.79 m with 4.88 active area, 120 Hz scan
rate) was used to assess spatial and temporal gait
parameters, according to the guidelines (Menz
et al. 2004; Kressig et al. 2006; Verghese et al. 2007;
Verlinden et al. 2013). The GAITRite Electronic
Walkway is a pressure sensitive mat, which registers
the spatial and temporal gait parameters of
participants walking over the mat. The GAITRite has
proven to be reliable and valid in healthy adults
(Bilney et al. 2003; Menz et al. 2004; Kressig
et al. 2006), people with Parkinson’s disease (Nelson
et al. 2002) and people with DS (Menz et al. 2004).
Test–retest reliability was established in elderly
people with cognitive impairment and people with DS
(Gretz et al. 1998; Montero-Odasso et al. 2009).
The following gait parameters were obtained and
studied: step length, stride length, base of support,
velocity, cadence, step time, stride time, stance time,
swing time, single and double support time, and the
standard deviation of stride time, as described in
Table 1. We focussed on these specific gait
parameters because in studies in the general
population, these parameters were found to be
associated with polypharmacy and/or antipsychotic
use (de Groot et al. 2016; Langeard et al. 2016;
Montero-Odasso et al. 2019).
Procedures
A human movement scientist and physical therapists,
who had experience with people with ID, performed
the measurements. All gait measurements were
performed by the same researcher. Measurements
were performed in a large room or a gym at the care
organisations. Participants performed four walks at
comfortable speed, meaning their usual walking
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speed, of which the first measurement was discarded
as a practice walk. To correct for possible acceleration
and deceleration, subjects started two meters before
the walkway and ended two meters after the walkway.
Statistical analyses
Normality of the data was checked and evaluated
sufficient. For the analysis to assess whether the gait
parameters differ between participants with and
without polypharmacy and participants using and not
using antipsychotics, the gait parameters were first
adjusted for leg length by dividing the parameters by
the mean leg length.
Personal characteristics and medical information of
the study sample were described for the total group,
the groups with and without polypharmacy and the
groups using and not using antipsychotics.
Differences between participants with and without
polypharmacy and participants using and not using
antipsychotics were assessed with independent t-tests
(for continuous variables) and χ2 square tests (for
categorical variables).
Gait parameters were described for the total
group, the groups with and without polypharmacy
and the groups using and not using antipsychotics.
Then independent t-tests were used to assess the
differences in gait parameters between participants
with and without polypharmacy and participants
using and not using antipsychotics. Effect sizes were
calculated with Cohen’s d, categorised into small
(0.2–0.49), medium (0.5–0.79) and large (≥0.8)
(Cohen 1992).
Because of a previous study with the same sample
that found sex and BMI to be associated with gait
(Oppewal et al. 2018), we subsequently assessed the
independent association of polypharmacy and using
antipsychotics with the gait parameters with multiple
linear regression analysis while correcting for sex and
BMI.
Analyses were performed with the Statistical
Package for Social Sciences (SPSS) version (IBM
Corporation, New York). P values < 0.05 were
considered statistically significant. Because of the
exploratory character of this study, no correction for
multiple testing was performed.
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Table 1 Definition of the gait parameters.
Gait parameter Definition
Spatial
parameters
Step length Distance between the heel centres of two consecutive opposite footprints on the line of progression (in cm).
Stride length Distance between the heel centres of two consecutive footprints of the same foot on the line of progression (in
cm).
Base of support Distance from the heel centre of one footprint to the line of progression formed by the heel centres of two
opposite footprints (in cm).
Temporal
parameters
Velocity Distance travelled divided by ambulation time (in cm/s).
Cadence Number of steps/minute.
Step time Time elapsed between first contact of one foot and first contact of the opposite foot (in s).
Stride time Time elapsed between the first contacts of two consecutive footfalls of the same foot (in s).
Stance time Time elapsed between the first contact and last contact of two consecutive footfalls on the same foot (in s). It is
initiated by heel contact and ends with toe off of the same foot.
Swing time Time elapsed between the last contact of the current footfall and the first contact of the next footfall of the same
foot (in s).
Single support time Time elapsed between the last contact of the opposite foot and the first contact of the next footfall of the opposite
foot (in s).
Double support timeAmount of time that two feet are on the ground at the same time within one footfall (in s).
Variability
Stride time SD Standard deviation in stride time (in s).
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Results
Descriptive statistics
The study population consisted of 31 adults with ID
with a mean age of 42.8 years (SD ¼ 16.7). The
population consisted predominantly of male
participants (24 male participants, 7 female
participants). Personal and medical information of
the total study sample, the groups with and without
polypharmacy and the groups using and not using
antipsychotics are described in Table 2.
Of the total study sample, 41.9% of the participants
had polypharmacy. Participants with polypharmacy
were significantly older (t ¼ 6.4, P < 0.001), and
more frequently used antiepileptics (n ¼ 8, χ2 ¼ 4.6,
P ¼ 0.032), antidepressants (n ¼ 5, χ2 ¼ 5.2,
P ¼ 0.022) and benzodiazepines (n ¼ 5, χ2 ¼ 5.2,
P ¼ 0.022). Of the total study sample, 48.4% used
antipsychotics. Of the people with polypharmacy,
61.5% used antipsychotics. In 53.3% of participants
with antipsychotics, polypharmacy was present.
There were no differences in personal characteristics
between participants using and not using
antipsychotics (Table 2).
Gait, polypharmacy and antipsychotic use
The gait parameters while walking at comfortable
speed are described in Table 3, for the total study
sample, and for the groups with and without
polypharmacy and the groups using and not using
antipsychotics.
Participants with polypharmacy had a shorter step
length (t ¼ 2.3, P ¼ 0.028, large effect size) and
stride length (t ¼ 2.3, P ¼ 0.028, large effect size).
When adjusting for sex and BMI, this difference
remained significant {regression model of step
length: polypharmacy B [standard error
(SE)] ¼ 0.079 [0.034], P ¼ 0.03; regression model
of stride length: polypharmacy B [SE] ¼ 0.157
[0.069], P ¼ 0.03} When adjusting for sex and BMI,
the difference in double support time also became
significantly different, with participants with
polypharmacy having a longer double support time
(polypharmacy B (SE) ¼ 0.0004 (0.0001),
P ¼ 0.047, medium effect size). We also saw a
medium effect size for the difference for the standard
deviation of stride time; however, this was not
significant.
Participants using antipsychotics had a significantly
longer double support time than those not using
antipsychotics (t ¼ 2.2, P ¼ 0.039, large effect size).
When adjusting for sex and BMI, this difference
remained significant (antipsychotic use B
(SE) ¼ 0.0003 (0.0002), P ¼ 0.019). We also saw a
medium effect size for gait velocity; however, this was
not significant.
Discussion
This cross-sectional, quantitative and exploratory
study was carried out to investigate the association
between polypharmacy, use of antipsychotics and gait
in adults with mild to moderate ID. After adjustment
for sex and BMI, people with polypharmacy had a
shorter step length (large effect size) and stride length
(large effect size) and a longer double support time
(medium effect size) than people without
polypharmacy. People using antipsychotics had a
significantly longer double support time (large effect
size) than those not using antipsychotics.
These results show that people with polypharmacy
seem to walk with smaller steps, and both people
with polypharmacy and people using antipsychotics
seem to spend more time with both feet on the
ground during the gait cycle. This resembles a more
cautious gait and could be a strategy to gain a better
balance. This supports our idea that using
antipsychotics or having polypharmacy influences
gait. This may lead to an increased risk for adverse
health outcomes; however, this has not yet been
studied.
Studies in the general population have also seen
associations between gait and polypharmacy;
however, these results could not be extrapolated for
people with ID due to the often pre-existing gait
disturbances and possible higher susceptibility to side
effects of medication (Matson and Mahan 2010;
Sheehan et al. 2017). Studies in the general
population showed more gait parameters to be
associated with polypharmacy (Gnjidic et al. 2012;
Langeard et al. 2016) such as lower velocity, stride
length, step length, and step width, and higher stride
time, variation in stride time, step time, and support
time (de Groot et al. 2016; Montero-Odasso
et al. 2019). A possible explanation for finding fewer
associations than studies in the general population
may be that gait disturbances are already often
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Table 2 Personal and medical information of the total study sample, and for the groups with and without polypharmacy and the antipsychotic
users and non-users.
Personal
characteristics
Total sample
n ¼ 31
Polypharmacy
n ¼ 13 (41.9%)
No polypharmacy
n ¼ 18 (58.1%)
Antipsychotic users
n ¼ 15 (48.4%)
Antipsychotic non-users
n ¼ 16 (51.6%)
Age (years),
M ± SD, range
42.8 ± 16.7,
20–68
57.5 ± 8.9**, 36–68 32.1 ± 12.2, 20–62 46.9 ± 16.3, 23–68 38.9 ± 16.7, 20–65
Sex
Female, n (%) 7 (22.6) 3 (23.1) 4 (22.2) 2 (13.3) 5 (31.3)
Male, n (%) 24 (77.4) 10 (76.9) 14 (77.8) r13 (86.7) 11 (68.8)
BMI M ± SD,
range
27.2 ± 4.5,
16.4–37.9
27.4 ± 4.8, 21.6–37.9 27.1 ± 4.4, 16.4–33.1 27.9 ± 4.2, 21.6–37.9 26.6 ± 4.9, 16.4–35.5
Normal, n (%) 9 (29.0) 4 (30.8) 5 (27.8) 3 (20.0) 6 (37.5)
Overweight, n
(%)
15 (48.4) 7 (53.8) 8 (44.4) 9 (60.0) 6 (37.5)
Obese, n (%) 7 (22.6) 2 (15.4) 5 (27.8) 3 (20.0) 4 (25.0)
Level of ID
Mild, n (%) 15 (48.4) 5 (38.5) 10 (55.6) 7 (46.7) 8 (50.0)
Moderate, n
(%)
16 (51.6) 8 (61.5) 8 (44.4) 8 (53.3) 8 (50.0)
Medical
information
Genetic
syndrome, n (%)
No genetic
syndrome
9 (29.0) 1 (7.7) 8 (44.4) 4 (26.7) 5 (31.3)
Phenylketonuria 1 (3.2) 0 1 (5.6) 0 1 (6.3)
Mosaic mutation
XLIS gene
1 (3.2) 1 (7.7) 0 1 (6.7) 0
Smith–Magenis
syndrome
1 (3.2) 1 (7.7) 0 0 1 (6.3)
Williams
syndrome
1 (3.2) 0 1 (5.6) 0 1 (6.3)
Perlman
syndrome
1 (3.2) 0 1 (5.6) 0 1 (6.3)
Unknown 17 (54.8) 10 (76.9) 7 (38.9) 10 (66.7) 7 (43.8)
Orthopaedic
shoes, n (%)
6 (19.4) 4 (30.8) 2 (11.1) 4 (26.7) 2 (12.5)
Spasticity arms, n
(%)
0 0 0 0 0
Spasticity legs, n
(%)
1 (3.2) 0 1 (5.6) 0 1 (6.3)
Medication use, n
(%)
Antipsychotics 15 (48.4) 8 (61.5) 7 (38.9) 15 (100) 0
Antidepressants 6 (19.4) 5 (38.5)* 1 (5.6) 4 (26.7) 2 (12.5)
Antiepileptics 3 (9.7) 3 (23.1)* 0 2 (13.3) 1 (6.3)
Anxiolytics 5 (16.1) 4 (30.8) 1 (5.6) 4 (26.7) 1 (6.3)
Benzodiazepines 6 (19.4) 5 (38.5)* 1 (5.6) 5 (33.3) 1 (6.3)
Polypharmacy 13 (41.9) 13 (100) 0 8 (53.3) 5 (31.3)
*P < 0.05,
**P < 0.01.
BMI, body mass index; ID, intellectual disability; M, mean; n, number of participants; SD, standard deviation.
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present in people with ID. Adults with ID seemed to
have a lower gait velocity, more variable and broader
gait pattern, and their gait is thought to already
resemble an older gait pattern at a relatively younger
age (Oppewal et al. 2018). These pre-existing gait
disturbances may mask the relative contribution of
polypharmacy on gait, or people with ID may already
have developed adaptation strategies to try to cope
with their disturbances, for example, to enhance
balance. The additional effect of medication use may
therefore be less clear.
The affected gait parameters (step length, stride
length and double support time) are all important
aspects of balance, reducing step and stride length
and increasing double support time can be a strategy
to create a more stable gait. However, one would then
also expect that velocity and base of support would be
different. We did find a large effect size for the
difference in velocity between people with and
without polypharmacy, with people with
polypharmacy having a lower velocity. However, this
difference was not significant, which may be because
of the small sample size of this study, and thereby
inadequate power to find significant results.
Studies concerning the effect of antipsychotic
medication on gait in the general population have
mostly focussed on falls (Hartikainen et al. 2007;
Bloch et al. 2011) or general movement disorders
(Matson and Mahan 2010). There was no record of a
study regarding the effect of antipsychotics on the
different gait parameters. We believe there are less
associations for the effect of antipsychotics on gait due
to the relatively small number of people that were
studied.
To know the exact contribution of medication use
on the gait of people with ID, it is needed to monitor
changes in gait while starting or stopping medication
or when the dose is changed. A direct comparison
with the general population will help in establishing
whether these effects in people with ID are different
than those seen in the general population.
Strengths and limitations
A strength of this study is that it is the first study to
investigate the association between polypharmacy and
the use of antipsychotics and gait in adults with ID.
This is an important topic to be addressed because of
the high prevalence of polypharmacy and antipsychotic
use in this population, the pre-existing gait
disturbances that are often seen, and the negative
health effects that gait disturbances can have. Further
strengths are the large number of gait parameters
studies, and that one specialised person, with
experience in working with people with ID, collected
all the gait data with the GAITRite, a reliable and valid
instrument providing objective data (Gretz et al. 1998;
Nelson et al. 2002; Bilney et al. 2003; Menz et al. 2004;
Kressig et al. 2006; Montero-Odasso et al. 2009).
However, this study also had some limitations. First,
because this was a secondary analysis of a study with a
different primary research question (study gait
characteristics of adults with ID, not causes by DS),
the study was not powered to answer the research
question in this article (Oppewal et al. 2018).
Therefore, this exploratory may have had in
inadequate statistical power to find significant results,
which limits generalisability of the results. Secondly,
because of this small sample size, it was not possible to
assess the association between gait and other sorts of
medication or dosages. Thirdly, the heterogeneous
group, consisting of mostly male participants, living in
care organisations may cause the sample to not be
representative for the overall population of people with
ID. Lastly, we have not looked at psychotropic
medication (antidepressants, antiepileptic’s,
anxiolytics and benzodiazepines) other than the
antipsychotic medication, due to the very small
subgroups it would create. This would be a
recommendation for future studies because others
types of psychotropic medication have proven to
negatively affect gait in the general population as well
(Hartikainen et al. 2007; Bloch et al. 2011), and people
with ID are thought to experience stronger side effects
(Matson andMahan 2010; Sheehan et al. 2017). Other
types of medication may also influence gait. For
example, cardiovascular medication might affect gait
due to orthostatic hypotension and unsteadiness,
which are common side effects of cardiovascular
medication such as antihypertensive medication or
statins (Pasternak et al. 2002; Mansourati 2012).
Lastly, because only people that could walk over the
GAITRite without any assistive devices were selected,
we may have excluded people who may have the most
severe motor problems or the ones that experience the
most severe side effects of medication on their gait.
The results of this study therefore might not be
generalisable to those groups.
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Conclusion
In conclusion, in people with ID, gait differed
between people with and without polypharmacy,
showing a shorter step and stride length and a longer
double support time in people with polypharmacy.
Furthermore, people with ID using antipsychotics
had a longer double support time. This exploratory
study highlights the importance to be aware of the
possible effects of medication use on gait in people
with ID. However, future prospective cohort studies,
with people starting or quitting medication, must be
done to gain more knowledge about the effects of
medication use, specific types of medication and
dosages of medication on the gait of adults with ID,
and about the effects of gait disturbances on health
outcomes in this population.
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